Loading data for PRME — first visit, this takes a few seconds.
Prime Medicine, Inc. (PRME)
NasdaqGM: PRME
· Real-Time Price · USD
3.13
-0.22 (-6.57%)
At close: Sep 11, 2026, 3:59 PM
3.18
+1.44%
After-hours: 7:58 PM
The price, the headline numbers and the latest news, in one place.
Prime Medicine, Inc. (PRME) Stock Price, Analysis & Data
-6.57% (1D)
| Bid | 2.24 |
| Market Cap | 568M |
| Revenue (ttm) | 4.07M |
| Net Income (ttm) | -188M |
| 2.35 | |
| -1.05 | |
| n/a | |
| -3.55 | |
| P/B (ttm) | 13.91 |
| P/S (ttm) | 139.38 |
| Earnings Date | Nov 6, 2026 |
| Ask | 3.71 |
| Volume | 3,071,786 |
| Avg. Volume (20D) | 3,288,796 |
| Open | 3.38 |
| Previous Close | 3.35 |
| Day's Range | 3.10 - 3.44 |
| 52-Week Range | 2.67 - 6.94 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PRME
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting i...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 20, 2022
Employees 146
Stock Exchange NasdaqGM
Ticker Symbol PRME
Website https://primemedicine.com
Financial Performance
In 2025, Prime Medicine's revenue was 4.63M, an increase of 55.28% compared to the previous year's 2.98M. Earnings were -201.14M, an increase of 2.69%.
Financial StatementsEarnings Surprise
Prime Medicine has released their quarterly earnings on Aug 6, 2026:
- Revenue of $1.15M misses estimates by $0, with 3.50% YoY growth.
- EPS of -0.24 exceeds estimates by 0.02, with 41.46% YoY growth.
Prime Medicine, Inc. is scheduled to release its earnings on Nov 6, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2